Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
ROS1 rearrangement
i
Other names:
ROS1, ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, V-Ros Avian UR2 Sarcoma Virus Oncogene Homolog 1, C-Ros Oncogene 1 Receptor Tyrosine Kinase, Proto-Oncogene Tyrosine-Protein Kinase ROS, Proto-Oncogene C-Ros-1, MCF3, ROS, V-Ros UR2 Sarcoma Virus Oncogene Homolog 1 (Avian), ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, Transmembrane Tyrosine-Specific Protein Kinase, Receptor Tyrosine Kinase C-Ros Oncogene 1, C-Ros Receptor Tyrosine Kinase, Proto-oncogene C-Ros, C-Ros-1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
6098
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
(15)
News
Trials
Search handles
@BollamRajesh4
@VivekSubbiah
@fedenichetti
@jsoriamd
@ns_chd
Search handles
@BollamRajesh4
@VivekSubbiah
@fedenichetti
@jsoriamd
@ns_chd
Filter by
Latest
10ms
It is, actually. And I'm praying not to see this happening in my own country which is notorious for his protective social security. In fact it is already happening in oncology for those in need of new targeted therapies for rare cancers like ALK- or ROS1-rearranged NSCLCs. (@indy_yet)
10 months ago
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ALK rearrangement • ROS1 rearrangement
12ms
It’s not really an issue of bias - simple biological plausibility. Mono-immunotherapy doesn’t / hasn’t / won’t work for EGFR mutated (& possibly ALK/ROS1 rearranged) NSCLC - that’s irrespective of what stage/indication it has been tested. Shouldn’t be attempted: that’s the tweet! (@ns_chd)
12 months ago
IO biomarker
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • ALK rearrangement • ROS1 rearrangement
1year
People with ALK, RET or ROS-rearranged #lungcancer often face oligoprogression - ie, disease progression in up to 5 sites even though any additional disease is under control. @Dingemans_anneM @DrSanjayPopat & Alessandra Bearz discuss the latest thinking https://t.co/nKF2oaDTu4 (@ALKpositiveINT)
1 year ago
Clinical
|
ALK (Anaplastic lymphoma kinase)
|
ALK rearrangement • ROS1 rearrangement
over1year
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial https://t.co/2DVgpy5ZFP (@VivekSubbiah)
over 1 year ago
Clinical
|
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ALK rearrangement • ROS1 rearrangement
|
Lorbrena (lorlatinib)
over1year
I'm glad to see a paper like this published! AC in cancer patients is tricky, now trying to identify cancer patients at highest risk of thrombosis important (ALK/ROS rearranged NSCLC, pancreatic, IDH WT neuroblastoma, etc, ccing @connors_md)! (@LeivaOrly)
over 1 year ago
Clinical
|
ALK (Anaplastic lymphoma kinase)
|
ALK rearrangement • ROS1 rearrangement • IDH wild-type
almost2years
Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1-Rearranged Non–Small-Cell Lung Cancer @JCOPO_ASCO https://t.co/W8fQa0GvET (@VivekSubbiah)
almost 2 years ago
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ROS1 rearrangement
|
Xalkori (crizotinib) • Zykadia (ceritinib) • Alunbrig (brigatinib)
over2years
Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1 Rearranged Non–Small-Cell Lung Cancer @notahedge @ASCO_pubs https://t.co/epI4NHAPmB (@VivekSubbiah)
over 2 years ago
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ROS1 rearrangement
|
Xalkori (crizotinib) • Zykadia (ceritinib) • Alunbrig (brigatinib)
over2years
Commenting on ros1 rearranged #lungcancer with crizotinib lack of penetration of blood brain barrier with moderator @ReckampK @PatelOncology @gotoPER #ilc2021 with cochairs @drgandara @DrRoyHerbstYale @HwakeleeMD (@donnashort)
over 2 years ago
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ROS1 rearrangement
|
Xalkori (crizotinib)
over2years
++ Got interested in Ceretinib after we saw 👉 Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report @PNASNews https://t.co/Jca2D5mtOE (@VivekSubbiah)
over 2 years ago
Clinical
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ROS1 rearrangement
|
Zykadia (ceritinib)
almost3years
Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1-Rearranged Non–Small-Cell Lung Cancer @notahedge @ASCO_pubs @ros1cancer #LCSM @Alfdoc2 @StephenVLiu @DrSteveMartin https://t.co/aMRewp9jlg (@VivekSubbiah)
almost 3 years ago
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ROS1 rearrangement
|
Xalkori (crizotinib) • Zykadia (ceritinib) • Alunbrig (brigatinib)
3years
Current treatment and future challenges in ROS1-rearranged #LCSM https://t.co/hgQ9PfttKx https://t.co/TMrnBIb1Wc @oncologician @VivekSubbiah @cspramesh @OncoAlert @IJMPOofficial (@BollamRajesh4)
3 years ago
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ROS1 rearrangement
3years
Current treatment and future challenges in ROS1-rearranged #LCSM https://t.co/gveuQx6IWc (@jsoriamd)
3 years ago
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ROS1 rearrangement
3years
Current treatment and future challenges in ROS1-rearranged #LCSM (@jsoriamd)
3 years ago
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ROS1 rearrangement
over3years
Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1 Rearranged Non–Small-Cell Lung Cancer @ASCO_pubs https://t.co/xZP1UNYyt7 (@VivekSubbiah)
over 3 years ago
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ROS1 rearrangement
|
Xalkori (crizotinib) • Zykadia (ceritinib) • Alunbrig (brigatinib)
over3years
WATCH: @benlevylungdoc, of @KimmelCancerCtr, discusses the efficacy of crizotinib versus entrectinib in ROS1-rearranged lung cancer. @gotoPER #gotoILCC #lcsm https://t.co/nrLNTi3iyQ (@OncLive)
over 3 years ago
Clinical
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ROS1 rearrangement
|
Xalkori (crizotinib) • Rozlytrek (entrectinib)
over3years
#ALK / #ROS1 rearrangements: a real hallmark for #thrombosis in #NSCLC patients? our new little work @icthicmagazine @marinagarassino https://t.co/UeSYoBmd59 (@fedenichetti)
over 3 years ago
Clinical
|
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ALK rearrangement • ROS1 rearrangement
almost4years
Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1-Rearranged Non–Small-Cell #LungCancer @ASCO_pubs @notahedge #LCSM https://t.co/qkxlixkF1y (@VivekSubbiah)
almost 4 years ago
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ROS1 rearrangement
|
Xalkori (crizotinib) • Zykadia (ceritinib) • Alunbrig (brigatinib)
almost4years
Drs. @Alexdrilon & Robert Mocharnuk assess recent data supporting the use of investigational therapies for the treatment of ROS1 rearrangement–positive #NSCLC. https://t.co/TNvJ3aEHTc (@ReachMD)
almost 4 years ago
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ROS1 positive • ROS1 rearrangement
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login